For people with diabetes, insulin is a potentially lifesaving medication. With ∼31% of U.S. adults with diabetes using some form of insulin (1), the importance of this medication in diabetes care cannot be overstated. To date, all available injectable insulin products require at least one daily injection, with many requiring multiple daily injections. The frequency of injections associated with insulin use can be a significant barrier for some individuals, with about one-third of individuals taking insulin reporting nonadherence to their insulin regimen (2). Insulin icodec, the first once-weekly basal insulin, is currently under review by the U.S. Food and Drug Administration (FDA) for use in the United States.
Insulin icodec is not yet approved by the FDA. If approved, it is expected to have an indication for both type 1 and type 2 diabetes.
Insulin icodec is a novel ultra-long-acting insulin formulation. It is administered through...
